Instrument Inactif

Autres langues Neon Therapeutics, Inc.

Actions

US64050Y1001

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

NEON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	06/05/20
Neon Therapeutics, Inc. Announces Management Changes	06/05/20
Neon Therapeutics, Inc.(NasdaqGS:NTGN) dropped from S&P TMI Index	06/05/20
BioNTech SE completed the acquisition of Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others.	06/05/20
NEON THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	05/05/20
Neon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	01/05/20
Neon Therapeutics, Inc. Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01	30/04/20
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01	30/04/20
Infinity Pharmaceuticals : Augments Board of Directors with Appointment of Richard Gaynor, M.D	18/03/20
NEON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	02/03/20
NEON THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	02/03/20
Neon Therapeutics : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update	02/03/20
Neon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	02/03/20
NEON THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neon Therapeutics, Inc. - NTGN	29/01/20
Neon Therapeutics : Biotechfirma BioNTech kauft US-Krebsspezialisten	16/01/20
NEON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	16/01/20
BioNTech SE entered into an Agreement to acquire Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others for $73.6 million.	16/01/20
Neon Therapeutics : Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01	18/12/19
Neon Therapeutics, Inc. Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01	18/12/19
NEON THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (form 8-K)	20/11/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neon Therapeutics, Inc.

Actions

US64050Y1001

Autres langues

Filtres